Drug
Luvadaxistat clinical trials
Also written TAK-831 and NBI-1065844.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses luvadaxistat is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaTerminatedPhase 2Neurocrine BiosciencesNCT05182476Written as Luvadaxistat
- A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of SchizophreniaCompletedPhase 2Neurocrine BiosciencesNCT03382639Written as Luvadaxistat
- A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With SchizophreniaCompletedPhase 2Neurocrine BiosciencesNCT03359785Written as Luvadaxistat
- A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy ParticipantsCompletedPhase 1Neurocrine BiosciencesNCT04234672Written as TAK-831 Oral Tablet
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy ParticipantsCompletedPhase 1Neurocrine BiosciencesNCT03224325Written as TAK-831 Tablet T2
- A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy ParticipantsCompletedPhase 1Neurocrine BiosciencesNCT03706469Written as TAK-831 T2
- Phase 1 Study of TAK-831 in Healthy Adult Asian SubjectsCompletedPhase 1Neurocrine BiosciencesNCT03687684Written as TAK-831
- Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich AtaxiaCompletedPhase 2Neurocrine BiosciencesNCT03214588Written as TAK-831
- Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral AdministrationCompletedPhase 1Neurocrine BiosciencesNCT02716987Written as TAK-831
- A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet FormulationCompletedPhase 1Neurocrine BiosciencesNCT03101293Written as TAK-831
- A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy ParticipantsTerminatedPhase 1Neurocrine BiosciencesNCT02566759Written as TAK-831 Oral Suspension
Codes
What other systems call luvadaxistat · ClinicalTrials.gg INT015413
- UNII (FDA) 76IC00YRVRLUVADAXISTATConfirmed FDA, Wikidata
- Wikidata Q106651232luvadaxistatConfirmed FDA, Wikidata
- NCI Thesaurus C175119LuvadaxistatOne source FDA
- DrugBank DB16067One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 76IC00YRVR | LUVADAXISTAT | Confirmed FDA, Wikidata |
| Wikidata | Q106651232 | luvadaxistat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175119 | Luvadaxistat | One source FDA |
| DrugBank | DB16067 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.